Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson's disease (EDAP).

ABSTRACT:

Introduction

Psychosis, including hallucinations and delusions, is one of the important non-motor problems in patients with Parkinson's disease (PD) and is possibly associated with cholinergic neuronal degeneration. The EDAP (Efficacy of Donepezil against Psychosis in PD) study will evaluate the efficacy of donepezil, a brain acetylcholine esterase inhibitor, for prevention of psychosis in PD.

Methods and analysis

Psychosis is assessed every 4 weeks using the Parkinson Psychosis Questionnaire (PPQ) and patients with PD whose PPQ-B score (hallucinations) and PPQ-C score (delusions) have been zero for 8 weeks before enrolment are randomised to two arms: patients receiving donepezil hydrochloride or patients receiving placebo. The patients are then followed for 96 weeks. The pr

SUBMITTER: Sawada H 

PROVIDER: S-EPMC3787472 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature